Tracking breast cancer changes during pre-surgery treatment
Part of Cancer, Skin clinical trials.
This study looks at how breast cancer changes while you are receiving chemotherapy or targeted therapy before surgery. The goal is to better understand which treatments work best for different types of breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with invasive breast cancer that has not spread beyond the breast or nearby lymph nodes.
- You are about to start chemotherapy, targeted therapy, or immunotherapy before surgery, but have not started yet.
- If your cancer is HER2-negative, you will receive a type of chemotherapy called a taxane. If your cancer is HER2-positive, you will receive anti-HER2 targeted therapy.
- You are 18 years or older.
- You are willing and able to give written permission to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
This trial looks at different drug combinations given before surgery to shrink breast tumors. The goal is to find which treatments work best for different types of breast cancer, such as triple-negative, HER2-positive, or hormone-receptor-positive. If you are a woman scheduled for neoadjuvant therapy (treatment before surgery) and have not had previous cancer treatment, this study may be for you.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This study looks back at treatments given to people with triple-negative or HER2-positive early breast cancer between 2016 and 2021. It aims to understand how treatment approaches have changed over time.
This trial tests a treatment given before breast surgery to shrink breast cancer and improve outcomes based on your tumor type. Your eligibility depends on tumor size/stage, hormone and HER2 markers, and overall health checks.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.